Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL3619340

Cc1c(Cl)cccc1S(=O)(=O)Nc1nc(CC(=O)N2CCN(C)CC2)cs1.O=C(O)C(F)(F)F

nearest known ligand 0.89

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 7/20 0.89
HSD17B1 P14061 2/20 0.89
HSD17B2 P37059 2/20 0.89
F2 P00734 4/20 0.44
F10 P00742 4/20 0.44
POLB P06746 2/20 0.43
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
LMNA P02545 1/20 0.40
ALK Q9UM73 1/20 0.39
CTPS1 P17812 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL368251 0.94 HSD11B1 (1.00) HSD11B1HSD17B1HSD17B2F2F10
Hydrochloric Acid SCHEMBL30044126 0.93 HSD11B1 (1.00) HSD11B1HSD17B1HSD17B2F2F10
Hydrochloric Acid SCHEMBL5692696 0.93 HSD11B1 (1.00) HSD11B1HSD17B1HSD17B2F2F10
Trifluoroacetic Acid SCHEMBL3617393 0.91 HSD11B1 (0.73) HSD11B1HSD17B1HSD17B2F2F10
SCHEMBL3616863 0.87 HSD11B1 (0.86) HSD11B1HSD17B1HSD17B2F2F10
SCHEMBL5693317 0.87 HSD11B1 (0.75) HSD11B1HSD17B1HSD17B2F2F10
SCHEMBL3606652 0.87 HSD11B1 (0.86) HSD11B1HSD17B1HSD17B2F2F10
SCHEMBL16325423 0.86 HSD11B1 (0.85) HSD11B1HSD17B1HSD17B2F2F10
SCHEMBL3616943 0.86 HSD11B1 (0.84) HSD11B1HSD17B1HSD17B2F2F10
SCHEMBL3614188 0.85 HSD11B1 (0.83) HSD11B1HSD17B1HSD17B2POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100113435-A1 INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 BIOVITRUM AB 2010-05-06 US claimed
US-7618961-B2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2009-11-17 US claimed
US-20040224996-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2004-11-11 US claimed
WO-2019075394-A1 COMPOUNDS FOR TREATMENT OF EMOTIONAL/PSYCHOLOGICAL SYMPTOMS IN FRAGILE X SYNDROME VANDERKLISH PETER (US) 2019-04-18 WO disclosed
US-20100113435-A1 INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 BIOVITRUM AB 2010-05-06 US disclosed
US-7618961-B2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2009-11-17 US disclosed
US-20040224996-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2004-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224996-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885HSD17B1 2/4885HSD17B2 5/4885
US-20100113435-A1 INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD3B1 HSD11B1 1/4885HSD17B1 2/4885HSD17B2 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.